DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS In this cohort study of 34,131 patients with cancer published in JAMA Oncology, trial ineligibility was associated with a greater likelihood of immune checkpoint inhibitor (ICI) monotherapy use compared with non-ICI therapy. Among trial-ineligible patients, there were no overall survival differences between treatment with ICI monotherapy, ICI combination therapy, and non-ICI therapy.
Peer-influenced content. Sources you trust. No registration required. This is HCN.